Okajima F, et al. - Researchers inspected the exact frequency of nocturnal hypoglycemia estimated with continuous glucose monitoring (CGM) in patients with type 2 diabetes who were admitted for glycemic control with basal–bolus insulin therapy (BBT), who were randomized into the Gla-100 and Gla-300 groups. No variation was reported between the 2 groups in the dose of meal-time insulin. Findings displayed that the reduction in the incidence of CGM-estimated nocturnal hypoglycemia by BBT under tightly controlled diet therapy was higher with Gla-300 than with Gla-100 in type 2 diabetic patients.